Press Release Archive
Press Releases
May 2020
05.14.2020 Research Vaccines Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age 05.13.2020 Finance Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day 05.12.2020 Research New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program 05.12.2020 Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 05.08.2020 Research Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting 05.05.2020 Research Vaccines Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program 05.04.2020 Research New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized 05.01.2020 Medicines Pfizer Receives Positive CHMP Opinion for DAURISMO®(glasdegib)for Certain Adult Patients with Newly Diagnosed or Secondary Acute Myeloid Leukemia (AML) 05.01.2020 Medicines Pfizer Receives Positive CHMP Opinion for DAURISMOTM (glasdegib)for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
April 2020
04.30.2020 Partnerships Vaccines Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15 04.30.2020 Partnerships AMRA Medical renews collaboration with Pfizer Inc. aiming to generate the world’s largest imaging dataset on body composition profiling 04.29.2020 Research Vaccines BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.